Volume 14

  • No. 4 December 2020
    In this issue...

    • Pfizer’s strategy for partnering success

    • Dealmaking in 2020 regains pace

    • The promise of microbiome therapeutics draws closer

    • Getting to the heart of genetic therapies

  • No. 3 September 2020
    In this issue...

    • Exploring new options for immuno-oncology cell therapies

    • Can antibodies combat the coronavirus crisis?

    • A snapshot of the CNS diseases market

    • Medtech dealmaking trends: a review

  • No. 2 June 2020
    In this issue...

    • The cell & gene therapy market matures

    • Wave of collaborations accelerate vaccine development

    • Dealmaking in 2020 faces new challenges

  • No. 1 March 2020
    In this issue...

    • Dealmaking in oncology diversifies

    • Biopharma’s big year for M&As